Back

Gender differences in cardio-oncology care of patients treated with immune checkpoint inhibitor therapy

27 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: T-cells, checkpoint inhibitors, and cardiac complications Cardio-Oncology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Raluca-Ileana Mincu

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)

7 More presentations in this session

Presentation thumbnail
Cardiovascular complications of chimeric antigen receptor (CAR)-T cell therapy
Associate Professor F. Guerra (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis
Doctor J. Heemelaar (Leiderdorp, NL)
Abstract Slides Video
Presentation thumbnail
Arterial inflammation induced by immune checkpoint inhibitors assessed on 18F-FDG PET-CT scans in stage III/IV melanoma patients
Miss E. Polomski (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Immune checkpoint inhibitors and atherosclerotic cardiovascular events: a retrospective cohort study
Doctor S. Tan (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels and reduces myocardial strain through NLRP3 and MyD-88 pathways
Doctor N. Maurea (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
T-cells, checkpoint inhibitors, and cardiac complications

The Event

Event poster

ESC Congress 2023

27 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Sex differences in diagnosis, prevention, and treatment of cardiotoxicity in cardio-oncology
thumbnail
Congress Presentation
Cardiovascular adverse events in primary lung cancer patients treated with immune checkpoint inhibitors: a nationwide database study
thumbnail
Congress Presentation
Immune checkpoint inhibitors and atherosclerotic cardiovascular events: a retrospective cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources